We performed a randomized trial of open-label ATV/r or EFV combined with abacavir/lamivudine ( ABC/3TC ) or tenofovir/emtricitabine ( TDF/FTC ) in 1857 human immunodeficiency virus type 1-infected , treatment-naive persons enrolled between September 2005 and November 2007 at 59 sites in the United States and Puerto Rico .